NEOMED Obstetrics and Gynecology

Topics

• Endometrial and Cervical Cancer Treatments 28
• Ovarian cancer diagnosis and treatment 23
• HER2/EGFR in Cancer Research 21
• Uterine Myomas and Treatments 16
• Preterm Birth and Chorioamnionitis 8
• PARP inhibition in cancer therapy 6
• Pelvic floor disorders treatments 6
• Maternal and fetal healthcare 5
• Maternal and Perinatal Health Interventions 5
• Cancer Cells and Metastasis 4
• Gestational Diabetes Research and Management 4
• Immunotherapy and Immune Responses 4

Most cited

1. Integrated mutational landscape analysis of uterine leiomyosarcomas.

   Proceedings of the National Academy of Sciences of the United States of America · 2021 · 105 citations · Masoud Azodi

2. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.

   Cancer · 2022 · 64 citations · Masoud Azodi

3. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

   Gynecologic oncology · 2023 · 27 citations · Masoud Azodi

4. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.

   Proceedings of the National Academy of Sciences of the United States of America · 2024 · 20 citations · Masoud Azodi

5. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.

   Gynecologic oncology · 2023 · 26 citations · Masoud Azodi

6. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

   Annals of oncology : official journal of the European Society for Medical Oncology · 2021 · 40 citations ·